Nativis Announces Publication of Study in Patients with Recurrent Glioblastoma (rGBM)

SEATTLE, Dec. 18, 2018 /PRNewswire-PRWeb/ -- Nativis, Inc., a clinical stage therapeutic device company developing non-invasive treatments for cancers and other serious diseases, today announced the publication of an early feasibility study in CNS Oncology suggesting that the Nativis Voyager device is safe for treatment of rGBM.

The publication of the study, An Early Feasibility Study of the Nativis Voyager® Device in Patients with Recurrent Glioblastoma: First Cohort in US, may be viewed HERE or on the Nativis web site.

"We are excited to have this publication accepted by CNS Oncology in conjunction with our internationally recognized clinical trial partners, led by Charles Cobbs, MD and Santosh Kesari, MD PhD," stated Chris Rivera, Nativis Chief Executive Officer. "The data in this early feasibility study not only suggest that the Nativis Voyager device is safe for the treatment of rGBM, but also that further studies to explore clinical utility are warranted."

The Nativis Voyager produces ultra-low radio frequency energy (ulRFE®) intended to induce a biologic response in solid tumors, such as rGBM. The ulRFE cognate is created by measuring and recording the oscillating magnetic field produced by molecules in solution. The recorded cognate is then used to reproduce the recorded magnetic field using an electromagnetic coil worn externally on the head by the patient.

"Nativis is grateful to our clinical partners, patients, and their families in this effort to develop an effective treatment for one of the most difficult diseases to treat known to medical science." Rivera went on to state, "Without the efforts of our dedicated and extraordinary clinical partners, our patients and their families would have fewer hopes to address the devastating effects of rGBM."

Rivera concluded, "We are looking forward to obtaining data from this ongoing clinical study for treatment of rGBM, with the expectation of producing safety and clinical utility results that are encouraging for our patients and their families."

About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage therapeutic device company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company's goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of medical conditions, as well as to veterinary medicine and non-medical applications. Nativis' initial focus is on the treatment of patients with brain cancer, who are not well served by conventional standard of care therapies, which often results in poor outcomes and devastating side effects. Additional pre-clinical work is focused on exploring new applications in other oncology settings and pain management. The Nativis Voyager system is an investigational medical device, limited by United States law to investigational use only.

Media Contact:
Dennis Kroft
dkroft(at)nativis(dot)com
201-602-8354

SOURCE Nativis